Google fires software engineer who claimed its AI chatbot is sentient

Author of the article: Alphabet Inc’s Google said on Friday it has dismissed a senior software engineer who claimed the company’s artificial intelligence (AI) chatbot LaMDA was a self-aware person. Google, which placed software engineer Blake Lemoine on leave last month, said he had violated company policies and that it found his claims on LaMDA…
Google fires software engineer who claimed its AI chatbot is sentient

Author of the article:

Alphabet Inc’s Google said on Friday it has dismissed a senior software engineer who claimed the company’s artificial intelligence (AI) chatbot LaMDA was a self-aware person.

Google, which placed software engineer Blake Lemoine on leave last month, said he had violated company policies and that it found his claims on LaMDA to be “wholly unfounded.”

“It’s regrettable that despite lengthy engagement on this topic, Blake still chose to persistently violate clear employment and data security policies that include the need to safeguard product information,” a Google spokesperson said in an email to Reuters.

Last year, Google said https://bit.ly/3Os9QqD that LaMDA – Language Model for Dialogue Applications – was built on the company’s research showing Transformer-based language models trained on dialog could learn to talk about essentially anything.

Google and many leading scientists were quick to dismiss Lemoine’s views as misguided, saying LaMDA is simply a complex algorithm designed to generate convincing human language.

Lemoine’s dismissal was first reported by Big Technology, a tech and society newsletter. (Reporting by Akanksha Khushi in Bengaluru; Editing by William Mallard)

Financial Post Top Stories

Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.

By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published.

Related Posts
Cash-strapped Britons give up pets as living costs soar
Read More

Cash-strapped Britons give up pets as living costs soar

Author of the article: LONDON — Stood on her hind legs to greet any prospective owner who might approach her glass-doored kennel, Harriet is a black English cocker spaniel abandoned as a deepening cost-of-living crisis pushes growing numbers of Britons to part with their pets. She was found running along a busy road in London…
Copper prices hover near 16-month lows on demand worries
Read More

Copper prices hover near 16-month lows on demand worries

Author of the article: LONDON — Copper prices held near 16-month lows on Wednesday as investors weighed the likelihood of rapid interest rate hikes hurting economic growth and metals demand. Industrial metals have tumbled alongside stock markets as central bankers stepped up talk of action to contain decades-high inflation. Benchmark copper on the London Metal…
Bond Turbulence Far From Over as Inflation Fears Haunt Fed Path
Read More

Bond Turbulence Far From Over as Inflation Fears Haunt Fed Path

Author of the article: Bloomberg News Liz Capo McCormick and Michael MacKenzie (Bloomberg) — Federal Reserve Chairman Jerome Powell beat back the market’s most aggressive predictions for the path of interest rates Wednesday, setting off a dovish surge in stocks and bonds. But in pouring cold water on the prospect for a jumbo-sized 75 basis…
China approves Brii Biosciences’ COVID-19 treatment
Read More

China approves Brii Biosciences’ COVID-19 treatment

This advertisement has not loaded yet, but your article continues below. Author of the article: Article content BEIJING — China’s medical products regulator said on Wednesday it has approved the use of BRII Biosciences’ neutrialising antibody cocktail for COVID-19, the first treatment of its type against the disease approved in the country. The medicine, a…